Firebrick Pharma Limited (FRE.AX)
AUD 0.08
(0.0%)
AUD 0.08
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -944.05 Thousand AUD | 86.25% |
| 2023 | -6.86 Million AUD | -81.0% |
| 2022 | -3.79 Million AUD | -32.51% |
| 2021 | -2.86 Million AUD | -42.52% |
| 2020 | -2 Million AUD | -71.13% |
| 2019 | -1.17 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -3.92 Million AUD | 42.78% |
| 2024 Q4 | -72.97 Thousand AUD | 0.0% |
| 2024 Q1 | -436.01 Thousand AUD | 88.19% |
| 2024 Q2 | -910.68 Thousand AUD | -108.87% |
| 2024 Q3 | -72.97 Thousand AUD | 91.99% |
| 2023 Q1 | -1.55 Million AUD | 30.91% |
| 2023 FY | -6.86 Million AUD | -81.0% |
| 2023 Q4 | -3.69 Million AUD | -102.93% |
| 2023 Q3 | -1.81 Million AUD | 42.22% |
| 2023 Q2 | -3.14 Million AUD | -102.36% |
| 2022 Q4 | -2.25 Million AUD | -102.71% |
| 2022 FY | -3.79 Million AUD | -32.51% |
| 2022 Q3 | -1.11 Million AUD | 13.64% |
| 2022 Q2 | -1.28 Million AUD | -100.0% |
| 2022 Q1 | -643.4 Thousand AUD | 65.81% |
| 2021 Q1 | -475.62 Thousand AUD | 0.0% |
| 2021 FY | -2.86 Million AUD | -42.52% |
| 2021 Q4 | -1.88 Million AUD | -152.86% |
| 2021 Q3 | -744.27 Thousand AUD | 21.76% |
| 2021 Q2 | -951.25 Thousand AUD | -100.0% |
| 2020 FY | -2 Million AUD | -71.13% |
| 2019 FY | -1.17 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Mayne Pharma Group Limited | -45.85 Million AUD | 97.941% |